CapsoVision, Inc. (CV)
Nasdaq · Electromedical & Electrotherapeutic Apparatus · Manufacturing · CIK 1378325 · fiscal year ends in Dec
Closing price $6.83 on 30 Oct 2026; 52-week range $4.59 to $14.42.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $13.9M
- Net income, last twelve months
- -$29.8M
- Gross margin
- 50.9%
- Operating margin
- -217.1%
- Net margin
- -214.7%
- Free cash flow
- -$27.9M
- Return on equity
- -226.6%
- Market value
- $341.7M
- Cash
- $9.1M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 50.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $13.6M | -$25.5M | -$25.3M | -$1.03 | -$23.0M | 10-K filed 26 Mar 2026 |
| FY2024 | 31 Dec 2024 | $11.8M | -$19.9M | -$19.9M | -$9.85 | -$20.2M | 10-K filed 26 Mar 2026 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $3.6M | -$7.5M | -$0.15 |
| Q1 FY2026 | 31 Mar 2026 | $2.8M | -$7.0M | -$0.15 |
| Q4 FY2025 | 31 Dec 2025 | $3.9M | -$7.4M | $1.73 |
| Q3 FY2025 | 30 Sep 2025 | $3.5M | -$7.9M | -$0.17 |
| Q2 FY2025 | 30 Jun 2025 | $3.3M | -$4.6M | -$0.10 |
| Q1 FY2025 | 31 Mar 2025 | $2.8M | -$5.4M | -$2.49 |
| Q3 FY2024 | 30 Sep 2024 | $3.0M | -$5.8M | -$2.79 |
| Q2 FY2024 | 30 Jun 2024 | $2.8M | -$5.3M | -$0.13 |
Company events
The newest 8-K filings of 19 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 28 Sep 2026 | 8-K | Other events | 8.01, 9.01 |
| 18 Sep 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 18 Aug 2026 | 8-K | Other events | 8.01, 9.01 |
| 13 Aug 2026 | 8-K | Results, Material agreement | 1.01, 2.02, 9.01 |
| 2 Jul 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01 |
| 12 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 20 Mar 2026 | 8-K | Results, Material agreement, Share sale, Investor update, Other events | 1.01, 2.02, 3.02, 7.01, 8.01, 9.01 |
| 13 Mar 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 29 Dec 2025 | 8-K | Other events | 8.01, 9.01 |
| 13 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 67 held.
| Filed | Form | Period |
|---|---|---|
| 28 Sep 2026 | 8-K | 25 Sep 2026 |
| 18 Sep 2026 | 8-K | 17 Sep 2026 |
| 21 Aug 2026 | EFFECT | – |
| 18 Aug 2026 | 8-K | 13 Aug 2026 |
| 13 Aug 2026 | S-3 | – |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 2 Jul 2026 | 8-K | 1 Jul 2026 |
| 12 Jun 2026 | 8-K | 11 Jun 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 28 Apr 2026 | DEF 14A | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 18 Sep 2026 | Harari Eliyahou Et Al, 10% owner | Purchase | 878,735 | $5.69 | $5.0M | 1,396,494 | 23 Sep 2026 |
| 18 Sep 2026 | Harari Eliyahou Et Al, 10% owner | Purchase | 878,734 | $5.69 | $5.0M | 878,734 | 23 Sep 2026 |
| 15 Sep 2026 | Shen Ching Hang, 10% owner | Purchase | 878,734 | $5.69 | $5.0M | 2,926,655 | 18 Sep 2026 |
| 17 Jul 2026 | Harari Eliyahou Et Al, 10% owner | Purchase | 61,068 | $6.73 | $411.0K | 3,343,119 | 21 Jul 2026 |
| 8 Jul 2026 | Harari Eliyahou Et Al, 10% owner | Purchase | 81,300 | $6.09 | $495.1K | 3,282,051 | 10 Jul 2026 |
| 26 Jun 2026 | Harari Eliyahou Et Al, 10% owner | Purchase | 13,850 | $7.35 | $101.8K | 3,200,751 | 7 Jul 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 6 May 2026 | Eliyahou Harari | 13G amended | 10.2% | 5.1M |
| 15 Apr 2026 | Shen Ching Hang | 13G amended | 12.8% | 6.4M |
| 7 Apr 2026 | CID Greater China Venture Capital Fund III, L.P. | 13G amended | 0% | 0 |
| 22 Dec 2025 | Shen Ching Hang | 13G | 8.5% | 4.0M |
| 12 Nov 2025 | Kioxia Corporation | 13G | 7.4% | 3.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.2M | +3.68% | 21.23 |
| 30 Sep 2026 | 2.1M | +10.81% | 5.44 |
| 15 Sep 2026 | 1.9M | +0.98% | 11.67 |
| 31 Aug 2026 | 1.9M | +5.27% | 23.03 |
| 14 Aug 2026 | 1.8M | -6.66% | 17.13 |
| 31 Jul 2026 | 1.9M | -9.29% | 21.05 |
| 15 Jul 2026 | 2.1M | +22.8% | 12.98 |
| 30 Jun 2026 | 1.7M | +16.71% | 5.32 |
Funds that hold it
From each fund's latest Form 13F.
55 funds held it at 30 Jun 2026: 36 added and 7 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 1,896,088 | $14.4M | +591,667 |
| Vanguard Capital Management LLC | 1,058,468 | $8.0M | +32,199 |
| Geode Capital Management, LLC | 578,482 | $4.4M | +143,328 |
| State Street Corp. | 410,241 | $3.1M | +154,200 |
| Vanguard Portfolio Management LLC | 240,425 | $1.8M | +76,039 |
| Northern Trust Corp. | 220,095 | $1.7M | +67,761 |
| Vanguard Fiduciary Trust Co. | 103,630 | $785.5K | +14,998 |
| Charles Schwab Investment Management Inc. | 79,360 | $601.5K | +17,983 |
| Bank of New York Mellon Corp | 75,021 | $568.7K | +25,727 |
| Nuveen, LLC | 46,011 | $348.8K | +12,913 |
Peers
Companies in the same industry.
- Medtronic plc (MDT): revenue $37.5B, market value $123.6B
- LivaNova plc (LIVN): revenue $1.5B, market value $4.3B
- Integer Holdings Corp. (ITGR): revenue $1.8B, market value $4.3B
- Axogen, Inc. (AXGN): revenue $266.9M, market value $2.9B
- TransMedics Group, Inc. (TMDX): revenue $668.5M, market value $2.3B
- Conmed Corp. (CNMD): revenue $1.4B, market value $1.3B
- Ceribell, Inc. (CBLL): revenue $102.0M, market value $1.0B
- Electromed, Inc. (ELMD): revenue $73.8M, market value $225.0M
- Edap TMS SA (FOCL): revenue –, market value $157.6M
- Neuraxis, Inc. (NRXS): revenue $5.3M, market value $89.3M